Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.
Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.
Exelixis (Nasdaq: EXEL) will present new data on CABOMETYX (cabozantinib) and investigational kinase inhibitor zanzalintinib at the ASCO 2026 Annual Meeting, held May 29–June 2 in Chicago.
Presentations span phase 2 and phase 3 trials across kidney cancer, neuroendocrine tumors, colorectal cancer, sarcoma, thyroid, urothelial and pediatric solid tumors.
Exelixis (Nasdaq: EXEL) announced a clinical development collaboration with Merck for the planned phase 3 pivotal trial STELLAR-316 in resected stage II/III colorectal cancer.
Exelixis will sponsor the trial, Merck will supply KEYTRUDA QLEX, and Natera’s Signatera assay will identify MRD+ patients. Trial initiation is expected in mid-2026.
Exelixis (NASDAQ: EXEL) will webcast management fireside chats at four investor conferences in May 2026. Presentations are scheduled for May 12 (BofA Health Care, 1:00 p.m. ET), May 19 (RBC, 9:00 a.m. ET), May 20 (Stifel virtual, 1:30 p.m. ET) and May 27 (Bernstein, 3:30 p.m. ET).
Webcasts and replays will be available at www.exelixis.com on the Event Calendar under Investors & News for at least 30 days.
Exelixis (Nasdaq: EXEL) reported Q1 2026 revenues of $610.8M, including cabozantinib U.S. net product revenues of $555.0M. GAAP diluted EPS was $0.79 and non-GAAP diluted EPS was $0.87. The company announced a new $750M stock repurchase program through end of 2027 and an FDA PDUFA date of Dec 3, 2026 for zanzalintinib.
Guidance for 2026 is maintained with total revenue guidance of $2.525B–$2.625B and R&D guidance of $875M–$925M.
Exelixis (Nasdaq: EXEL) will release its first quarter 2026 financial results on Tuesday, May 5, 2026 after the market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
Access is available via the company website Event Calendar under Investors & News; a replay will be archived for one year.
Exelixis (Nasdaq: EXEL) will webcast management fireside chats at four investor conferences in March. Presentations are scheduled on March 3, March 10 and March 11 with session times listed in ET and PT.
Webcasts and replays will be available via the company website Event Calendar under Investors & News, with replays accessible for at least 30 days.
Exelixis (Nasdaq: EXEL) reported Q4 2025 total revenues $598.7M and FY2025 total revenues $2.320B. U.S. cabozantinib net product revenues were $546.6M (Q4) and $2.123B (FY). GAAP diluted EPS was $0.88 (Q4) and $2.78 (FY). The FDA accepted the NDA for zanzalintinib with a PDUFA date of Dec 3, 2026. FY2026 guidance: total revenues $2.525B–$2.625B, net product revenues $2.325B–$2.425B, R&D $875M–$925M, SG&A $575M–$625M.
Exelixis (Nasdaq: EXEL) announced that the U.S. FDA accepted its New Drug Application for zanzalintinib combined with atezolizumab for previously treated metastatic colorectal cancer.
The FDA set a standard review PDUFA target action date of December 3, 2026. The NDA is supported by phase 3 STELLAR-303, which showed a statistically significant overall survival benefit versus regorafenib in the intention-to-treat population; some endpoint data remain immature with a planned final analysis expected in mid-2026.
Exelixis (Nasdaq: EXEL) will release fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026 after market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT to discuss results and provide a business update.
Access is available via the company website Event Calendar under Investors & News; registrants for the call receive a dial-in number and unique PIN. A webcast replay will be archived on the website for one year.
Exelixis (Nasdaq: EXEL) reported preliminary unaudited fiscal 2025 results and issued 2026 guidance. Key figures include cabozantinib U.S. net product revenues of ~$2.123 billion for FY2025 and FY2026 net product revenue guidance of $2.325–$2.425 billion (assumes a 3.0% U.S. WAC increase). Fiscal 2025 R&D was ~$825 million and FY2026 R&D guidance is $875–$925 million. Ending cash and marketable securities were ~$1.65 billion. The company highlighted multiple mid-2026 clinical readouts for zanzalintinib and ongoing pivotal trials, plus an additional $750 million share repurchase authorization.